Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Oncología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy
INTERVENTIONAL
Inicio: 11 de mar de 2014
ID: NCT02008227
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)
INTERVENTIONAL
Inicio: 6 de dic de 2023
ID: NCT06077760
Completado
Fase 3
ClinicalTrials.gov
A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere®) Plus Cisplatin and 5-Fluorouracil (TPF) Versus Neoadjuvant Cisplatin Plus 5-Fluorouracil Followed by Concomitant Chemoradiotherapy to Improve the Overall Survival and Progression Free Survival in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
INTERVENTIONAL
Inicio: 1 de may de 1999
ID: NCT00273546
Completado
Fase 3
ClinicalTrials.gov
a Phase 3 Randomized Double Blind Evaluation of LY353381 Compared With Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
INTERVENTIONAL
ID: NCT00034125
Completado
Fase 2
ClinicalTrials.gov
An Open-label, Phase II, Single-arm Study of Everolimus in Combination With Letrozole in the Treatment of Postmenopausal Women With Estrogen Receptor Positive HER2 Negative Metastatic or Locally Advanced Breast Cancer
INTERVENTIONAL
Inicio: 7 de mar de 2013
ID: NCT01698918
Completado
Fase 3
ClinicalTrials.gov
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Patients Receiving Myelosuppressive Treatment Regimens Requiring Platelet Transfusion Support.
INTERVENTIONAL
Inicio: 1 de dic de 1999
ID: NCT00037791
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Pleural Mesothelioma
INTERVENTIONAL
Inicio: 23 de sept de 2021
ID: NCT04914897
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)
INTERVENTIONAL
Inicio: 5 de jun de 2024
ID: NCT06211036
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy
INTERVENTIONAL
Inicio: 7 de dic de 2020
ID: NCT04658862
Completado
ClinicalTrials.gov
Multicentre NIS Retrospective Study to Know the Prevalence of HER2- Low,Clinical Characteristics,Treatment Patterns,Associated Outcome in Patient With HER2-negative in Metastatic Breast Cancer Who Progressed on Systemic Anticancer Therapy
OBSERVATIONAL
Inicio: 23 de abr de 2024
ID: NCT06131424
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
INTERVENTIONAL
Inicio: 23 de jun de 2022
ID: NCT04975997
Completado
ClinicalTrials.gov
REFINE: Regorafenib Observational Study in Hepatocellular Carcinoma
OBSERVATIONAL
Inicio: 13 de sept de 2017
ID: NCT03289273
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM First)
INTERVENTIONAL
Inicio: 1 de sept de 2016
ID: NCT02668653
Activo, no recluta
Fase 3
ClinicalTrials.gov
Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)
INTERVENTIONAL
Inicio: 26 de abr de 2021
ID: NCT04784715
Desconocido
ClinicalTrials.gov
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
EXPANDED_ACCESS
ID: NCT01947608
Reclutando
Fase 2
ClinicalTrials.gov
A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment With Inavolisib Combinations in Patients With Untreated, Early-stage, PIK3CA-Mutated Breast Cancer
INTERVENTIONAL
Inicio: 9 de sept de 2025
ID: NCT07054190
Completado
Fase 3
ClinicalTrials.gov
Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab Plus Etoposide/Platinum Versus Etoposide/Platinum in Subjects With Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)
INTERVENTIONAL
Inicio: 13 de dic de 2011
ID: NCT01450761
Completado
Fase 2
ClinicalTrials.gov
A Randomized Open-Label, Phase II Study of Lapatinib-capecitabine or Lapatinib-vinorelbine or Lapatinib/Gemcitabine in Subjects With Her2/Neu Amplified Metastatic Breast Cancer Patients Progression After Taxanes Treatment
INTERVENTIONAL
Inicio: 1 de nov de 2009
ID: NCT01050322
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
INTERVENTIONAL
Inicio: 23 de sept de 2024
ID: NCT06497556
Activo, no recluta
Fase 3
ClinicalTrials.gov
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
INTERVENTIONAL
Inicio: 14 de abr de 2022
ID: NCT05288166
Anterior
1
...
63
64
65
...
434
Siguiente
Filtros